| ||Clinigene International Enters into Collaborative Clinical Research Services Agreement with Pacific Biomarkers | 12/21/2011 1:09:26 PM|| |
| ||Biocon Ltd has informed BSE regarding a Press Release dated December 21, 2011 titled "Clinigene International Enters into Collaborative Clinical Research Services Agreement with Pacific Biomarkers"|
Clinigene International Limited, a subsidiary of Biocon, India's largest Biotech Company, and Pacific Biomarkers Inc. (PBI), a Seattle, WA-based limited liability company announce a collaborative agreement to address the specialty biomarker and high-end clinical trial laboratory needs of the global pharmaceutical and biotechnology industry.
Clinigene, is an India-based Clinical Research Organization (CRO) that offers end-to-end clinical and laboratory services for accelerating clinical research, and Pacific Biomarkers Inc. (PBI), is a Seattle, WA-based company that provides premier biomarker and specialty efficacy testing services to the drug development industry.
"PBI is a recognized global leader in providing specialty biomarkers and clinical diagnostic assay services to discovery- and development-based life science enterprises. We are delighted that PBI has selected Clinigene as its partner in India and we look forward to supporting PBI in extending and expanding its specialist service offerings," said Peter Bains, Director of Research Services business.
"This partnership with Clinigene provides us access to India, an emerging hub for drug development and contract research. Further, Clinigene's state-of-the-art facilities and highly qualified staff help us offer to all of our clients an economic option to conduct their biomarker and specialty clinical lab tests. We are also excited about Clinigene's unique capabilities in cell-based assays and immunoanalytical testing services, which are of great interest to the global pharmaceutical and biotechnology community," said Ronald Helm, CEO of Pacific Biomarkers."